All In MedTech

Device Trial Radar · NCT06512324

Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry

Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry (OBSERVER)

Last checked: Nov 20, 2026Latest source record: Jul 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

5,000

Planned (sponsor's estimate)

Start

Jun 27, 2024

Primary completion

Aug 30, 2028

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Biomedical Discoveries and Neuroscientific Foundations LLCNot on our public-company list
Sponsor type
Industry
First posted
Jul 22, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) or generalized anxiety disorder (GAD). The main questions it aims to answer are: 1. Which factors have the greatest causal role in mediating the effectiveness of TMS in improving symptoms of depression (and/or anxiety)? 2. Which factors have a minimal causal role in mediating the effectiveness of TMS in improving symptoms of depression (and/or anxiety)? Participants already undergoing TMS as part of their treatment plan for MDD/GAD answer survey questions about their symptoms before, during, and up to 1 year post-treatment. Factors affecting clinical outcomes such as stimulation parameters, behavioral factors, physiological factors, patient characteristics, and pharmacological factors, are also recorded.

Conditions

  • Major Depressive Disorder
  • MDD
  • Generalized Anxiety Disorder
  • GAD
  • Depression
  • Anxiety

Interventions

  • Ampa One TMS SystemDevice

    Transcranial Magnetic Stimulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 9-item Patient Health Questionnaire (PHQ-9) [or PHQ-9-A if appropriate]Time frame: Administered weekly from baseline up to 1 year from the end of treatment.
  2. 7-item General Anxiety Disorder Questionnaire (GAD-7) [or GAD-10-A if appropriate]Time frame: Administered weekly from baseline up to 1 year from the end of treatment.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kind Health Group

    Encinitas, California

  • Salience Research Institute

    Plano, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.